Oligonucleotide therapies: a new class of drugs that allow precise genetic targeting

19 October 2021

Delivered by Annemieke Aartsma-Rus on 19th october 3-4pm CEST
The speaker is Professor of Translational Genetics at the Department of Human Genetics at the Leiden University Medical Center in the Netherlands. She has an interest on the development of antisense oligo nucleotides treatments, namely for Duchenne muscular dystrophy.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern